¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Primarily systemic and haematological agent, unspecified"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • systemic embolism
    Àü½Å»öÀüÁõ
  • systemic hypotension
    Àü½ÅÀúÇ÷¾Ð
  • systemic infection
    Àü½Å°¨¿°
  • systemic inflammatory response syndrome
    Àü½Å¿°Áõ¹ÝÀÀÁõÈıº
  • systemic lesion
    °èÅ뺴ÅÍ
  • systemic lupus erythematosus
    Àü½ÅÈ«¹Ý·çǪ½º
  • systemic mastocytosis
    Àü½Åºñ¸¸¼¼Æ÷Áõ
  • systemic nodular panniculitis
    Àü½Å°áÀýÁö¹æÃþ¿°
  • systemic reaction
    Àü½Å¹ÝÀÀ
  • systemic scleroderma
    Àü½ÅÇǺΰæÈ­Áõ
  • systemic sclerosis
    Àü½Å°æÈ­Áõ
  • systemic therapy
    Àü½Å¿ä¹ý
  • systemic treatment
    Àü½ÅÄ¡·á
  • systemic vein
    Àü½ÅÁ¤¸Æ, üÁ¤¸Æ
  • anorectic agent
    ½Ä¿å¾ïÁ¦Á¦
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • tocolytic agent
    ÀڱüöÃà¾ïÁ¦Á¦
  • toxic agent
    µ¶¹°, µ¶±Ø¹°
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • exudative chronic discoid and lichenoid dermatitis
    »ïÃ⸸¼º¿ø¹Ýż±ÇǺο°
  • foot-and-mouth disease
    ÀԹ߱Áº´, ±¸Á¦¿ª
  • incision and drainage
    Àý°³¹è³ó
  • wear and tear dermatitis
    ¹Ýº¹ÀÚ±ØÇǺο°
  • embryonal and botryoid rhabdomyosarcoma
    ¹è¾ÆÆ÷µµÈ¾¹®±ÙÀ°Á¾
  • salt-and-pepper fundus
    ÈÄÃ߼ұݸð¾ç¾ÈÀú, ÈÄÃ߼ұݸð¾ç´«¹Ù´Ú
  • left and right handedness
    ¾ç¼ÕÀâÀÌ
  • maternal and child health
    ¸ðÀÚº¸°Ç
  • maternity and infant hygiene
    ¸ð¼º¿µ¾ÆÀ§»ý
  • intake and output record
    ¼·Ãë¹è¼³·®±â·Ï
  • perfusion and diffusion imaging
    °ü·ùÈ®»ê¿µ»ó
  • law of weights and measures
    °è·®¹ý
  • trial-and-error learning
    ½ÃÇàÂø¿ÀÇнÀ
  • to and fro motion
    ¿Õº¹¿îµ¿
  • picture archiving and communicating system
    ¿µ»óÀúÀå¹×Àü¼Ûü°è
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • SOFAS, Social and Occupational Functioning Assessment Scale
    »çȸ-Á÷¾÷±â´ÉÆò°¡Ã´µµ
  • SONAR(Sound Navigation and Ranging)
    ¼Ò³ª
  • acute and late normal tissue effects
    Á¤»óÁ¶Á÷ ±Þ¼º¿µÇâ, Á¤»óÁ¶Á÷ ¸¸¼º ¿µÇâ
  • alternate hot and cold caloric examination
    ³Ã¿Â±³´ë(¿Âµµ)Àڱذ˻ç(ÕÒè®Îßû»è®öôô§Ð½ËþÞÛ).
  • ambient temperature and pressure saturated with water vapor =ATP
    ½Ç¿Â´ë±â¾Ð ¼öÁõ±â Æ÷È­»óÅÂ
  • american society of therapeutic radiology and onco
    logy (ASTRO) ¹Ì±¹¹æ»ç¼±Á¾¾çÇÐȸ
  • aphthous fever =foot and mouth disease
    ¾ÆÇÁŸ¼º¿­(¡­æð).
  • glioma of optic nerve and chiasm
    ½Ã½Å°æ±³Â÷ ±³¼¼Æ÷Á¾.
  • glycerin and potash solution
    ±Û¸®¼¼¸° Ä®·ý¾×.
  • gray matter (nuclei and columns)
    ȸ»öÁú(½Å°æÇÙ°ú ½Å°æ±âµÕ)
  • half and half nail
    ¹Ý¹Ý Á¶°©
  • hand and foot disease
    ¼ö Á· Áúȯ£¨â¢ðëòðü´£©£¬¼Õ ¹ß º´, ¼ö Á· º´ (â¢ðëÜ»).
  • hand foot and mouth disease
    ¼Õ¹ßÀÔº´ (¡­Ü»), ¼öÁ·±¸º´(â¢ðëϢܻ).
  • hand foot and mouth disease
    ¼Õ¹ßÀÔº´ (¡­Ü»), ¼öÁ·±¸º´(â¢ðëϢܻ)
  • heat and acetic acid test
    °¡¿Â¾Æ¼¼Æ®»ê½ÃÇè (¹ý)(ʥ计­ß«ãËúÐÛö).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • secondary systemic amyloidosis
    ¼Ó¹ß¼º Àü½Å¼º(áÙÛ¡àõîïãóàõ) ¾Æ¹Ð·ÎÀ̵åÁõ.
  • secondary systemic amyloidosis
    ¼Ó¹ß¼º Àü½Å¼º(áÙÛ¡àõîïãóàõ) ¾Æ¹Ð·ÎÀ̵åÁõ(¡­ñø)
  • sle= systemic lupus erythematosus
    Àü½Å¼º È«¹Ý¼º ·çǪ½º(îïãóàõ ûõÚèàõ¡­)
  • systemic amyloidosis
    Àü½Å¼º ¾Æ¹Ð·ÎÀ̵åÁõ
  • systemic blood pressure
    üÇ÷¾Ð(ô÷úìäâ).
  • systemic circulation
    ü¼øÈ¯(ô÷âàü»)
  • systemic circulation
    ü¼øÈ¯(ô÷âàü»).
  • systemic death
    Àü½Å»ç(îïãóÞÝ)
  • systemic herpes zoster
    Àü½Å ´ë»ó Æ÷Áø
  • systemic hypotension
    Àü½Å¼º ÀúÇ÷¾Ð(Áõ)(îï ãóàõî¸úìäâñø).
  • systemic hypotension
    Àü½Å¼º ÀúÇ÷¾Ð(Áõ)(îï ãóàõî¸úìäâñø)
  • systemic infection
    Àü½Å¼º °¨¿°(Áõ) (¡­Êïæøñø).
  • systemic inflammatory response sydrome
  • systemic lesion
    Àü½Å¼º º´º¯(¡­Ü»Ü¨)
  • systemic lupus erythematosus
    Àü½Å¼ºÈ«¹Ý¼º·çÇÁ½º
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • F agent
    F Á¦(ð¥)
  • fusogenic agent
    À¶ÇÕ »ý¼ºÁ¦(ë×ùêßæà÷ð¥)
  • germicidal agent
    »ì±ÕÁ¦(߯жð¥)
  • immunosuppressive agent
    ¸é¿ª¾ï¾ÐÁ¦(Øóæ¹åääâð¥)
  • lipotropic agent
    ÁöÁúµ¿¿øÁ¦(ò·òõÔÑê¬ð¥)
  • lympholytic agent
    ¸²ÇÁ±¸¿ëÇØÁ¦(éÁú°ð­)
  • lysosomotropic agent
    ¶óÀ̼ÒÁ»ÀÚ±ØÁ¦(í©Ð»ð¥)
  • methylating agent
    ¸ÞƿȭÁ¦(ð¥)
  • mutagenic agent
    º¯ÀÌ¿øÁ¦(ܨì¶ê«ð¥)
  • oxidizing agent
    »êÈ­Á¦(ß«ûùð¥)
  • precipitating agent
    ħ°­Á¦(öØË½ð¥)
  • pressor agent
    Ç÷¾Ð»ó½ÂÁ¦(úìäâß¾ã°ð¥)
  • reducing agent
    ȯ¿ø ½Ã¾à(ü½êªãËå·)
  • sequestering agent
    °ÝÀýÇü¼ºÁ¦(̰ï¾û¡à÷ð¥)
  • sulfating agent
    Ȳ»êÈ­Á¦ (üÜß«ûùð¥)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • paramagnetic agent
    »óÀÚ¼ºÁ¦Àç
  • protective agent
    º¸È£¾à, ÇÇÆ÷¾à
  • radioopaque agent
    ¹æ»ç¼±ºñÅõ°ú¼ºÁ¦Àç
  • radioprotective agent
    ¹æ»ç¼±¹æÈ£Á¦
  • sclerosing agent
    °æÈ­¾à
  • therapeutic agent
    Ä¡·á¾à
  • thrombolytic agent
    Ç÷Àü¿ëÇØ¾à
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
SPS scapuloperoneal syndrome; shoulder pain and stiffness; simple partial seizures; slow-progressive sch...
SR sarcoplasmic reticulum; saturation recovery; scanning radiometer; screen; secretion rate; sedimentat...
DTIC Dimethyl Triazeno Imidazole Carboxamide
  ; Alkylating Agent
HDV Hepatitis D(elta) Virus
  = HBV associated Delta Agent
AAA abdominal aortic aneurysm/aneurysmectomy; acne-associated arthritis; acquired aplastic anemia; acute...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
MAP Mean systemic arterial pressure
MSAP Mean systemic arterial pressure
NP-SLE Neuropsychiatric Systemic Lupus Erythematosus
PSE Portal systemic encephalopathy
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • cheek and tongue retractor
    Çù¼³ °ßÀαâ
  • child abuse and neglect
    ¾Æµ¿ Çдë¿Í ¹æÄ¡
  • communication codes and characteristics
    È­ÀÇ ºÎÈ£¿Í ¼ºÁú
  • congenital and developmental bone disorder
    ¼±Ãµ¼º ¹× ¹ßÀ°¼º °ñ Àå¾Ö
  • congenital and developmental muscle disorder
    ¼±Ãµ¼º ¹× ¹ßÀ°¼º ±ÙÀå¾Ö
    Ãâ»ý ½ÃºÎÅÍ ±ÙÀúÇϸ¦ ³ªÅ¸³»°í Èå´ÃÈå´ÃÇÑ ¾ÆÀÌ. flo
  • connective tissue sheath of Key and Retzius
    Ű-·¹Ä¡¿ì½ºÀÇ °áÇÕ Á¶Á÷ ÃÊ
    ½Å°æ³»¸·, ƯÈ÷ ½Å°æ¼¶À¯ Á¾¸»Áö ÁÖÀ§ÀÇ ¾ãÀº ¿¬Àå.
  • crown and loop space maintainer
    Å©¶ó¿î¿£µå ·çÇÁÇü °£°Ý À¯Áö ÀåÄ¡
  • cultural and ethnic factor
    ¹®È­ ¹ÎÁ·Àû ¿äÀÎ
  • D and C ÀÚ±ÃÀÇ °æºÎ È®Àå°ú ³»¸· ¼ÒÆÄ.

    D factor

    D-ÀÎÀÚ
  • development of speech and language
    ÀÇ»ç ¼ÒÅëÀÇ ¹ß´Þ
  • ear nose and throat
    À̺ñÀÎÈİú
    ÈĵÎ, ºñ°­, ÀεΠµîÀ» Àü¹®À¸·Î ÇÏ´Â ÀÇÇÐÀÇ ÇÑ ºÐ°ú.
  • exostosis and osteoma
    ¿Ü°ñÁõ ¹× °ñÁ¾
    »À Á¶Á÷ÀÇ °ú¹ßÀ°Àº Åë»ó ¿ì¿¬È÷ ¹ß°ßµÇ´Â °ÍÀÌ ´ëºÎºÐÀÌ°í °¡²û ÀÓ»óÀûÀ¸·Î Àǹ̰¡ ÀÖ´Â °æ¿ì¸¦ º»´Ù. ÀÓ»óÀûÀ¸·Î ÇǺηΠµ¤Èù µÕ±Ù °ñ Á¶Á÷ÀÌ ¿ÜÀ̵µÀÇ ³»Ãø¿¡¼­ °í¸·À» °¡¸®¸ç °üÂûµÈ´Ù. ÀϺο¡ ±¹ÇÑµÈ ´ÜÀÏÀÇ °ñÁ¾Àº ¿ÜÀ̵µ¸¦ ¿ÏÀüÈ÷ ¸·°Å³ª °¨¿°À» ÀÏÀ¸Å°Áö ¾Ê´Â ÇÑ ¹®Á¦°¡ ¾øÀ¸³ª ¶§·Î Â÷°¡¿î ¹°¿¡ Áö¼ÓÀûÀ¸·Î ³ëÃâµÈ °ÍÀÌ ¿øÀÎÀ¸·Î Áö¸ñµÇ±âµµ ÇÏ´Â ´Ù¹ß¼º °ñÁ¾ÀÇ °æ¿ì´Â Á¡Â÷ ÁøÇàµÇ¾î ¼ö¼úÀÌ ÇÊ¿äÇϱ⵵ ÇÏ´Ù.
  • explosion and fire hazard
    Æø¹ß ÀÎÈ­¼º À§Çè
  • Food and Drug Administration
    ½ÄǰÀǾà±â±¸
  • H and D curve
    Ư¼º °î¼±
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
agent <pharmacology> Any power, principle or substance capable of producing an effect, whether physical, chemical or biological.
Origin: L. Agens = acting
(18 Nov 1997)
agent, antihypertensive As the name suggests, a drug aimed at reducing high blood pressure (hypertension).
(12 Dec 1998)
agent, anti-infective Something capable of acting against infection, by inhibiting the spread of an infectious agent or by killing the infectious agent outright.
(12 Dec 1998)
Agent Orange An herbicide and defoliant, consisting of (2,4,5-trichlorophenoxy)acetic acid, (2,4-dichlorophenoxy)acetic acid, and dioxin, that was widely used in the Vietnam War; it has been shown to possess residual post-exposure carcinogenic and teratogenic properties in humans.
(05 Mar 2000)
agent, tocolytic A medication that can inhibit labour, slow down or halt the contractions of the uterus. Tocolytic agents are widely used today to treat premature labour and permit pregnancy to procede and so let the foetus gain in size and maturity before being born.
(12 Dec 1998)
alkylating agent <oncology, pharmacology> A reagent that places an alkyl group, for example propyl in place of a nucleophilic group in a molecule. Alkylating reagents include a number of cytotoxic drugs some of which react fairly specifically with N7 of the purine ring and lead to depurination of DNA, for example the agent ethyl ethanesulphonic acid and thus to mutagenesis. The drugs interaction with DNAand prevents the division of the cells.
Examples of drugs include: busulphan, chlorambucil, cyclophosphamide, melphalan.
(29 Sep 1997)
alpha-adrenergic blocking agent An agent that competitively blocks alpha-adrenergic receptors; used in the treatment of hypertension.
Synonym: alpha-blocker.
(05 Mar 2000)
antianxiety agent A functional category of drugs useful in the treatment of anxiety and able to reduce anxiety at doses which do not cause excessive sedation (e.g., diazepam).
Synonym: anxiolytic, minor tranquilliser.
(05 Mar 2000)
antidiabetic agent A substance that helps a person with diabetes control the level of glucose (sugar) in the blood so that the body works as it should. See: insulin.
(09 Oct 1997)
antifibrinolytic agent Agents that prevent fibrinolysis or lysis of a blood clot or thrombus. Several endogenous antiplasmins are known. The drugs are used to control massive haemorrhage and in other coagulation disorders.
(12 Dec 1998)
antifoam agent A chemical that reduces the surface tension of foams that form on thesurface of broths in fermentors because of aeration or agitation. Stearyldecanol, octal decanol, vegetable oils, silicones, sulphonates, andpolypropylene glycol are typically used, though they can cause problems inrefining the broth later on.
(09 Oct 1997)
anti-inflammatory agent Agents that counteract or suppress the inflammatory process. An antirheumatic agent or inflammation mediator, both endogenous and exogenous substances used to counteract the inflammatory process or alleviate or prevent rheumatic diseases, and the compounds that mediate the inflammation process.
(12 Dec 1998)
anti-inflammatory agent, non-steroidal Anti-inflammatory agents that are not steroids. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They are used primarily in the treatment of chronic arthritic conditions and certain soft tissue disorders associated with pain and inflammation. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. Certain nsaids also may inhibit lipoxygenase enzymes or phospholipase c or may modulate T-cell function. (ama drug evaluations annual, 1994, p 1814-5)
(12 Dec 1998)
anti-inflammatory agent, steroidal Steroidal agents capable of suppressing or counteracting the inflammatory process by acting on body mechanisms, without directly antagonizing the causative agents.
(12 Dec 1998)
anti-inflammatory agent, topical Anti-inflammatory agent that are applied to the skin and whose pharmacological effect only occurs at the area of application.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • publicity agent
    ±¤°í ´ë¸®¾÷ÀÚ
  • purchasing agent
    ±¸¸Å ´ã´ç
  • reducing agent
    ȯ¿øÁ¦
  • road agent
    ³ë»ó°­µµ
  • secret agent
    øº¸¿ø;Á¤º¸¿ø;°£Ã¸
  • shipping agent
    ÇØ¿î¾÷ÀÚ
  • station agent
    ¿ªÀå
  • universal agent
    ÃѴ븮Á¡
  • again and again
    ¹Ýº¹Çؼ­
  • and
    ±×¸®°í
  • and not ~ either
    ¶Ç ~ ¾Æ´Ï´Ù(=nor)
  • and so forth
    ±âŸ µîµî
  • and so on
    ..µîµî
  • and such
    µûÀ§,µîµî
  • and that
    ±×°Íµµ,°Ô´Ù°¡
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á